Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients

Cancer Genetics and Cytogenetics

Volumn 195, Issue 2, 2009, Pages 179-182

  Masago, Katsuhiro ^a   Fujita, Shiro ^b   Kim, Young Hak ^a   Ichikawa, Masataka ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Nagai, Hiroki ^a   Irisa, Kaoru ^a   Mio, Tadashi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL;

ADULT; AGED; CONTROLLED STUDY; DRUG RESPONSE; EXON; FEMALE; GENE ACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; JAPANESE; LETTER; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; SOMATIC MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; EXONS; HUMANS; JAPAN; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70949096018     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.06.025     Document Type: Letter

References (24)

1. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., Oh D.Y., Kim J.H., Kim D.W., Chung D.H., Im S.A., Kim Y.T., Lee J.S., Heo D.S., Bang Y.J., and Kim N.K. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
2. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T., Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., and Tsai S.F. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10 (2004) 8195-8203
3. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba II, Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., and Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
4. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., Ichimura K., Tsuda T., Yano M., Tsukuda K., Tabata M., Ueoka H., Tanimoto M., Date H., Gazdar A.F., and Shimizu N. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11 (2005) 1167-1173
5. Chou T.Y., Chiu C.H., Li L.H., Hsiao C.Y., Tzen C.Y., Chang K.T., Chen Y.M., Perng R.P., Tsai S.F., and Tsai C.M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 3750-3757
6. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R.P., and Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). [corrected] [Erratum in: J Clin Oncol 2004;22:4811]. J Clin Oncol 21 (2003) 2237-2246
7. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., Sgroi D.C., Muir B., Riemenschneider M.J., Iacona R.B., Krebs A.D., Johnson D.H., Giaccone G., Herbst R.S., Manegold C., Fukuoka M., Kris M.G., Baselga J., Ochs J.S., and Haber D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
8. Cappuzzo F., Finocchiaro G., Metro G., Bartolini S., Magrini E., Cancellieri A., Trisolini R., Castaldini L., Tallini G., and Crino L. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 58 (2006) 31-45
9. Cortes-Funes H., Gomez C., Rosell R., Valero P., Garcia-Giron C., Velasco A., Izquierdo A., Diz P., Camps C., Castellanos D., Alberola V., Cardenal F., Gonzalez-Larriba J.L., Vieitez J.M., Maeztu I., Sanchez J.J., Queralt C., Mayo C., Mendez P., Moran T., and Taron M. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16 (2005) 1081-1086
10. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., Bunn Jr. P.A., Franklin W.A., Crowley J., and Gandara D.R. Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23 (2005) 6838-6845
11. Kim K.S., Jeong J.Y., Kim Y.C., Na K.J., Kim Y.H., Ahn S.J., Baek S.M., Park C.S., Park C.M., Kim Y.I., Lim S.C., and Park K.O. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11 (2005) 2244-2251
12. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
13. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., and Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
14. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
15. Rosell R., Ichinose Y., Taron M., Sarries C., Queralt C., Mendez P., Sanchez J.M., Nishiyama K., Moran T., Cirauqui B., Mate J.L., Besse B., Reguart N., Perez M., and Sanchez J.J. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50 (2005) 25-33
16. Sonobe M., Manabe T., Wada H., and Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93 (2005) 355-363
17. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., Yamamoto S., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Shibata T., Sakiyama T., Yoshida T., and Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
18. Tomizawa Y., Iijima H., Sunaga N., Sato K., Takise A., Otani Y., Tanaka S., Suga T., Saito R., Ishizuka T., Dobashi K., Minna J.D., Nakajima T., and Mori M. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 6816-6822
19. Nagai Y., Miyazawa H., Huqun T.T., Udagawa K., Kato M., Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., and Hagiwara K. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 65 (2005) 7276-7282
20. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., Tanaka T., Miyazawa H., Nagata M., Kanazawa M., Hagiwara K., and Kobayashi K. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95 (2006) 1483-1489
21. Tanaka T., Nagai Y., Miyazawa H., Koyama N., Matsuoka S., Sutani A., Huqun U.K., Murayama Y., Nagata M., Shimizu Y., Ikebuchi K., Kanazawa M., Kobayashi K., and Hagiwara K. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 98 (2007) 246-252
22. Vikis H., Sato M., James M., Wang D., Wang Y., Wang M., Jia D., Liu Y., Bailey-Wilson J.E., Amos C.I., Pinney S.M., Petersen G.M., de Andrade M., Yang P., Wiest J.S., Fain P.R., Schwartz A.G., Gazdar A., Gaba C., Rothschild H., Mandal D., Kupert E., Seminara D., Viswanathan A., Govindan R., Minna J., Anderson M.W., and You M. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 67 (2007) 4665-4670
23. Sriuranpong V., Chantranuwat C., Huapai N., Chalermchai T., Leungtaweeboon K., Lertsanguansinchai P., Voravud N., and Mutirangura A. High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. Cancer Lett 239 (2006) 292-297
24. Zhang G.C., Lin J.Y., Wang Z., Zhou Q., Xu C.R., Zhu J.Q., Wang K., Yang X.N., Chen G., Yang J.J., Huang Y.J., Liao R.Q., and Wu Y.L. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol) 19 (2007) 499-506